

Product datasheet

Anti-Ras antibody [EPR3255] ab108602

Recombinant **RabMAb**

★★★★☆ 1 Abreviews 6 References 1 Image

Overview

Product name	Anti-Ras antibody [EPR3255]
Description	Rabbit monoclonal [EPR3255] to Ras
Host species	Rabbit
Specificity	ab108602 also detects H-Ras and N-Ras.
Tested applications	Suitable for: WB, IP, ICC Unsuitable for: Flow Cyt or IHC-P
Species reactivity	Reacts with: Mouse, Rat, Human
Immunogen	Synthetic peptide within Human Ras aa 1-100 (N terminal). The exact sequence is proprietary.
Positive control	WB: 293T and SH-SY5Y cell lysates.
General notes	Our RabMAb [®] technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb[®] patents This product is a recombinant rabbit monoclonal antibody.

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
Storage buffer	pH: 7.20 Preservative: 0.01% Sodium azide Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Purity	Tissue culture supernatant
Clonality	Monoclonal
Clone number	EPR3255
Isotype	IgG

Applications

Our [Abpromise guarantee](#) covers the use of **ab108602** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
WB	★★★★☆	1/1000 - 1/10000. Predicted molecular weight: 22 kDa.
IP		1/10 - 1/100.
ICC		1/50 - 1/100.

Application notes Is unsuitable for Flow Cyt or IHC-P.

Target

Function Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.

Involvement in disease Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.

Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.

Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.

Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.

Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).


Sequence similarities Belongs to the small GTPase superfamily. Ras family.

Post-translational modifications Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.

S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.

Cellular localization Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.

Images



All lanes : Anti-Ras antibody [EPR3255] (ab108602) at 1/1000 dilution

Lane 1 : 293T cell lysate

Lane 2 : SH-SY5Y cell lysate

Lysates/proteins at 10 µg per lane.

Secondary

All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

Predicted band size: 22 kDa

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors